I-ne Co., Ltd. Full-Year (4Q) Earnings Preview

Strong performance of new BOTANIST lines and gross profit margin improvement provide tailwinds; focus is on the likelihood of a significant 4Q profit recovery and full-year guidance achievement

PublishedMay 13, 2026 at 15:30 GMT+9

Summary

I-ne is an asset-light (fabless) beauty maker whose competitive advantages lie in "brand creation capability," "OMO (Online Merges with Offline)," and "IPTOS" (its proprietary product development process). The company pursues cross-category growth across haircare, beauty appliances, and skincare, anchored by three core brands: BOTANIST, SALONIA, and YOLU. Through 3Q cumulative, the gross profit margin improved +4.4pp to 57.6% (vs. 53.2% in the year-ago period), and portfolio expansion benefits from M&A (Artemis and Tout Vert) are beginning to materialize. However, a sharp increase in SG&A and the amortization burden from intangible assets weighed on operating income, leaving the guidance achievement rate for operating income at just 43.8%. The central question heading into full-year results is whether the company can clear the high hurdle of JPY 2,833M in standalone 4Q operating income (our estimate: +79% YoY). Additionally, the company disclosed a revision to its full-year guidance on February 12, 2026, drawing attention to both the revised landing level and the directional signals for next fiscal year's guidance.

Key Points for Next Quarter

Key Points & Focus	Implications
Revenue GrowthFull-year revenue landing vs. company guidance of JPY 52,000M	3Q cumulative achievement rate at 66.1%. Standalone 4Q requires JPY 17,635M (our estimate), implying +28.6% growth vs. prior-year 4Q actual (our estimate: ~JPY 13,711M). The achievement level may shift depending on the content of the guidance revision
Profit RecoveryStandalone 4Q operating income level and EBITDA margin	Achieving full-year guidance requires standalone 4Q operating income of JPY 2,833M (our estimate). The key question is whether OPM can converge from 6.4% on a 3Q cumulative basis to the 9.7% full-year guidance target
SG&A ControlQuarterly trajectory of SG&A ratio and advertising efficiency	3Q cumulative SG&A ratio at 51.2% (vs. 43.7% in the year-ago period). Organic SG&A efficiency excluding M&A-related intangible asset amortization (3Q cumulative D&A of JPY 1,298M vs. JPY 290M in the year-ago period) is critical
Segment ProfitabilityDomestic segment profit margin and overseas P&L improvement	Domestic segment profit margin declined to 13.7% on a 3Q cumulative basis (vs. 18.1% YoY). Overseas operating loss improved to JPY -169M (vs. JPY -603M YoY), and the timeline to breakeven post-China withdrawal is a key focus
Guidance RevisionContent of the full-year guidance revision disclosed on February 12, 2026	Magnitude and rationale for revisions to revenue and each profit line item, and implications for next fiscal year's guidance. Reports of an earnings release postponement also warrant caution on landing accuracy
Shareholder ReturnsDividend level following the increase and future return policy	Year-end DPS guidance raised from JPY 13 to JPY 15. Room for further improvement in payout ratio (our estimate: ~9.7% based on full-year EPS of JPY 154.42) and the impact of an expanded shareholder benefits program merit confirmation
M&A Integration BenefitsProgress on brand strategy post-subsidiarization of Artemis and Tout Vert	With goodwill at JPY 5,916M (16.8% of total assets) following the subsidiarization of Artemis and Tout Vert, assessing integration synergy realization is key

Key Issues from Previous Results (FY2025/12 3Q Results)

3Q cumulative consolidated revenue grew steadily at JPY 34,365M (+9.8% YoY), while operating income continued its declining trajectory at JPY 2,207M (−25.4% YoY). Despite ongoing improvement in the gross profit margin, the increase in intangible asset amortization from M&A and front-loaded promotional investments weighed on profits. The extent to which the company can recoup the profit shortfall vs. full-year guidance in 4Q will be the decisive factor in the final assessment of this fiscal year.

1. Likelihood of a Sharp Standalone 4Q Profit Recovery

Prior Period
: 3Q cumulative operating income of JPY 2,207M; guidance achievement rate of 43.8% against full-year guidance of JPY 5,040M
This Quarter Verification
: Whether standalone 4Q operating income of JPY 2,833M (our estimate) can be booked. The year-end selling season (fukubukuro/lucky bags, Christmas campaigns) and new product launches driving revenue upside, combined with seasonal variability in promotional spend, are the key levers
Key Metrics
: Standalone 4Q OPM (our estimate: ~16.1% on a guidance basis), QoQ change in SG&A

Achieving the full-year guidance requires an extremely high profit contribution from 4Q, necessitating scrutiny of plan credibility.

2. Sustainability of Structural Gross Margin Improvement

Prior Period
: COGS of JPY 14,562M, gross profit of JPY 19,803M (gross margin 57.6%)
This Quarter Verification
: Product mix improvement effects from acquired brands (Tout Vert, etc.), and the full-year margin contribution from raw material costs and FX impacts
Key Metrics
: Full-year gross profit margin trajectory, gross margin structure by segment

The 3Q cumulative gross profit margin improved +4.4pp to 57.6% (vs. 53.2% YoY); the key is whether this improvement is transient or structural.

3. Intangible Asset Amortization Burden from M&A and Integration Synergies

Prior Period
: Goodwill of JPY 5,916M, contract-related assets of JPY 2,999M, trademarks of JPY 2,492M, customer-related assets of JPY 694M (total intangible fixed assets of JPY 12,338M)
This Quarter Verification
: Progress on group structure optimization following the absorption merger of Endeavour (effective December 1, 2025), and the revenue contribution of Tout Vert's skincare brand
Key Metrics
: EBITDA (3Q cumulative JPY 3,505M, full-year guidance JPY 6,760M, achievement rate 51.8%) standalone 4Q level, and any impairment risk on goodwill and other intangibles

Following the acquisition of Artemis and Tout Vert in October 2024, D&A surged from JPY 290M to JPY 1,298M YoY, widening the gap between EBITDA and operating income.

4. Overseas P&L Improvement and Growth Strategy Restructuring

Prior Period
: Overseas revenue of JPY 792M (−17.2% YoY), operating loss of JPY -169M (JPY 434M improvement vs. JPY -603M YoY)
This Quarter Verification
: Progress on sales channel expansion in Hong Kong, Taiwan, South Korea, and Southeast Asia; timing of revenue contribution from BOTANIST's U.S. Costco rollout (~250 stores)
Key Metrics
: Quarterly breakeven timeline for the overseas business, drawdown status of the business restructuring loss reserve (JPY 156M)

Following the decision to dissolve and liquidate the Chinese subsidiary (I-ne (Shanghai)), the overseas business turnaround is underway.

5. Balance Sheet Health and Changes in Funding Structure

Prior Period
: Merchandise inventories of JPY 5,388M (vs. JPY 3,503M at prior fiscal year-end, +53.8%), equity ratio of 49.5% (vs. 42.9% at prior fiscal year-end), interest-bearing debt of JPY 6,963M
This Quarter Verification
: Improvement in inventory turnover at 4Q-end (progress of inventory sell-through during the year-end selling season), full-year impact of interest expense (3Q cumulative JPY 48M)
Key Metrics
: Net D/E ratio, free cash flow level, changes in working capital

While JPY 10,000M in short-term borrowings for M&A funding was refinanced into long-term debt (JPY 5,678M + JPY 1,285M current portion of long-term debt), inventories have surged.

Timely Disclosure & Industry Trends

2026/02/12
Revision of FY2025/12 Full-Year Consolidated Guidance — The company revised its full-year guidance, which had been left unchanged at the 3Q stage. Details of the revision need to be confirmed at the full-year earnings release; this is a critical disclosure that will significantly influence the 4Q landing level. I-ne Earnings Materials — IRBANK
2025/12/04
Management DX Award Grand Prize — External recognition for the company's DX initiatives in management operations. Direct earnings impact is limited, but it signals progress in operational efficiency. I-ne Timely Disclosures — IRBANK
2025/11/19
Change in Effective Date of Absorption Merger and Planned Debt Waiver — Procedural changes related to the absorption merger of Endeavour. Indicates progress in group restructuring. I-ne Timely Disclosures — IRBANK
2025/11/07
Revision of Year-End Dividend Forecast (Increase) and Expansion of Shareholder Benefits Program — Year-end DPS raised from JPY 13 to JPY 15, with shareholder benefits also expanded. Signals strengthened shareholder return stance. I-ne IR

Previous Quarter Results (FY2025/12 3Q Actual)

I-ne is an asset-light (fabless) beauty maker with BOTANIST, SALONIA, and YOLU as its core brands, leveraging SNS marketing and data-driven product development (IPTOS) to carve out a differentiated position in the haircare, beauty appliance, and skincare markets. In October 2024, the company subsidiarized Artemis (formerly TTrading) and Tout Vert, accelerating its expansion into skincare. 3Q cumulative revenue maintained near double-digit growth at +9.8% YoY, but operating income declined −25.4% due to M&A-related costs (goodwill and intangible asset amortization) and expanded upfront investments.

Item	Amount	YoY	vs. Company Guidance	Remarks
Revenue	JPY 34,365M	+9.8%	Achievement Rate 66.1%	Domestic +10.6%, overseas −17.2% (China withdrawal impact)
Operating Income	JPY 2,207M	−25.4%	Achievement Rate 43.8%	SG&A +28.4% (intangible asset amortization increase)
Recurring Profit	JPY 2,111M	−28.4%	Achievement Rate 42.2%	FX losses JPY 105M, interest expense JPY 48M
Net Income Attributable to Owners of Parent Company	JPY 1,105M	−29.8%	Achievement Rate 40.9%	Contract losses JPY 97M (extraordinary losses)
EPS	JPY 63.24	−29.3%	-	Weighted average shares outstanding: 17,486K

Guidance Achievement Rate (Revenue): 66.1% (year-ago period: ~69.5%, our estimate)